Pacific Edge at risk of losing ‘significant’ revenue stream

Pacific Edge at risk of losing ‘significant’ revenue stream
The test has been used more than 10,000 times since it was first approved in 2020. (Image: Pacific Edge)
Dan Brunskill
Pacific Edge could have its cancer tests dropped by a major US health insurance company which is considering a new way to choose which tests are covered.  Medicare provider Novitas currently reimburses the use of Cxbladder but would not under a new process it has proposed. Currently, the health insurer reviews clinical evidence for each individual product but has proposed relying on third-party lists instead. Pacific Edge said if the proposal was adopted, Cxbladder would no longer receive reimbursement from Novitas, which makes up &ld...

More Markets

Surviving Trump's ‘whack-a-mole’ tariffs
Markets

Brian Robins: Surviving Trump's ‘whack-a-mole’ tariffs

Trump's end game is to curtail China's trade position.

NZ sharemarket up nearly 0.5%, third rise this week
Markets Market Close

NZ sharemarket up nearly 0.5%, third rise this week

The S&P/NZX 50 Index gained 56.99 points or 0.44% to 13,000.56.

Graham Skellern 16 Jan 2025
NZ sharemarket lifts off after Auckland Airport numbers
Markets Market close

NZ sharemarket lifts off after Auckland Airport numbers

The S&P/NZX 50 Index closed at 12,943.57, gaining 59.19 points or 0.46%.

Graham Skellern 15 Jan 2025
Auckland Airport numbers bounce back
Markets

Auckland Airport numbers bounce back

Numbers highest since the pandemic hit five years ago.

Staff reporters 15 Jan 2025